SK Biopharmaceuticals Co. is expanding its epilepsy treatment portfolio through a new joint venture with Brazil’s Eurofarma Laboratórios to develop an artificial intelligence-based platform in the United States.
The South Korean drugmaker plans to combine its AI technology for electroencephalogram analysis and wearable monitoring devices with Eurofarma’s manufacturing capabilities. The partnership builds on their 2022 licensing agreement that gave Eurofarma rights to make and sell SK’s anti-seizure drug Cenobamate in Latin America.
The companies are targeting North America’s tele-epilepsy market, which they project will represent 47% of global demand by 2032. SK Biopharm CEO Lee Donghoon said the venture will focus on developing predictive AI models for epileptic seizures by integrating clinical data into digital platforms.
SK Biopharm, a unit of South Korea’s SK Group conglomerate, began selling Cenobamate under the brand name Xcopri in the US in 2020 after FDA approval. The drug marked SK’s first independent development from research through commercialization.
The Korean company aims to reach an enterprise value of 50 trillion won ($44 billion) by 2030. The digital health sector is expected to grow 25% annually, with significant investment flowing into AI-driven diagnostics and treatment management.
